Jacob Lalezari of CytoDyn shares insights about CCR5-targeting therapy for cancer, including triple negative breast cancer and colorectal cancer.
Leronlimab-mediated CCR5 blockade modulates T-Cell exhaustion pathways and PD-L1 Biology relevant to ICI responseDurable Clinical Observations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results